Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Future Medicinal Chemistry|March 16, 2012
Current limitations and future opportunities for epigenetic therapiesF Cherblanc, N Chapman-Rothe, R Brown, et al.
Allergy|March 25, 2016
Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trialP Staubach, M Metz, N Chapman-Rothe, et al.
Allergy|October 24, 2017
Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study dataP Staubach, M Metz, N Chapman-Rothe, et al.
Oncogene|November 7, 2012
Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cellsN Chapman-Rothe, E Curry, C Zeller, et al.
Allergy|October 12, 2013
Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholinesM Hotze, H Baurecht, E Rodríguez, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|February 5, 2017
H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE studyM Maurer, P Staubach, U Raap, et al.
The World Allergy Organization Journal|November 23, 2018
Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE studyM Maurer, K Houghton, C Costa, et al.
Pageof 1